Key Points
- Insider sale: Kevin Mcculloch sold 15,000 Xeris Biopharma shares at an average price of $8.49 for $127,350 under a pre-arranged Rule 10b5-1 plan. He continues to own 1.64 million shares.
- Financial performance: Xeris reported quarterly revenue of $92.1 million, exceeding expectations, but posted a loss of $0.18 per share versus the $0.01 consensus estimate.
- Analyst outlook: The stock has an average “Hold” rating and a $12 target price; Barclays raised its target to $12 with an “overweight” rating, while other analysts issued more cautious assessments.
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Get Free Report) insider Steven Pieper sold 5,000 shares of the firm's stock in a transaction that occurred on Tuesday, September 1st. The stock was sold at an average price of $8.50, for a total transaction of $42,500.00. Following the sale, the insider directly owned 1,356,053 shares of the company's stock, valued at approximately $11,526,450.50. The trade was a 0.37% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Steven Pieper also recently made the following trade(s):
- On Wednesday, August 12th, Steven Pieper sold 5,000 shares of Xeris Biopharma stock. The shares were sold at an average price of $8.50, for a total transaction of $42,500.00.
- On Tuesday, July 7th, Steven Pieper sold 27,600 shares of Xeris Biopharma stock. The stock was sold at an average price of $8.52, for a total value of $235,152.00.
- On Monday, July 6th, Steven Pieper sold 17,400 shares of Xeris Biopharma stock. The shares were sold at an average price of $8.50, for a total value of $147,900.00.
Xeris Biopharma Stock Performance
Shares of NASDAQ:XERS opened at $8.43 on Wednesday. The business has a fifty day moving average of $8.34 and a 200-day moving average of $6.95. The company has a debt-to-equity ratio of 17.00, a quick ratio of 1.02 and a current ratio of 1.45. Xeris Biopharma Holdings, Inc. has a twelve month low of $5.25 and a twelve month high of $10.08. The firm has a market cap of $1.54 billion, a PE ratio of -76.64 and a beta of 0.66.
Xeris Biopharma (NASDAQ:XERS - Get Free Report) last announced its earnings results on Thursday, August 6th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.01 by ($0.19). The company had revenue of $92.10 million for the quarter, compared to analyst estimates of $90.12 million. Xeris Biopharma had a positive return on equity of 338.21% and a negative net margin of 5.12%. On average, equities research analysts predict that Xeris Biopharma Holdings, Inc. will post 0.07 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
A number of research firms have recently weighed in on XERS. Wall Street Zen downgraded Xeris Biopharma from a "strong-buy" rating to a "buy" rating in a research report on Saturday, August 8th. Weiss Ratings lowered Xeris Biopharma from a "hold (c-)" rating to a "sell (d-)" rating in a research report on Tuesday, August 11th. Finally, Barclays boosted their price objective on Xeris Biopharma from $9.00 to $12.00 and gave the stock an "overweight" rating in a report on Thursday, August 20th. Three research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, Xeris Biopharma currently has a consensus rating of "Hold" and an average price target of $12.00.
Get Our Latest Analysis on XERS
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Corient Private Wealth LP acquired a new stake in shares of Xeris Biopharma during the second quarter worth $1,458,000. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new position in Xeris Biopharma in the second quarter valued at about $89,000. California State Teachers Retirement System boosted its holdings in Xeris Biopharma by 720.4% during the second quarter. California State Teachers Retirement System now owns 1,479,456 shares of the company's stock worth $11,717,000 after buying an additional 1,299,117 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in Xeris Biopharma by 2.9% during the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 687,632 shares of the company's stock worth $5,446,000 after buying an additional 19,558 shares during the last quarter. Finally, Hsbc Holdings PLC grew its position in shares of Xeris Biopharma by 34.0% during the 2nd quarter. Hsbc Holdings PLC now owns 41,779 shares of the company's stock worth $330,000 after buying an additional 10,604 shares during the period. 42.75% of the stock is currently owned by institutional investors.
About Xeris Biopharma
(
Get Free Report)
Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company's proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.
The company's flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
